MedicaNatumin AB (publ) said its normalized net income for the third quarter came to 1.6 million kronor, a rise of 47.1% from 1.1 million kronor in the year-earlier period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
The normalized profit margin increased to 5.2% from 5.2% in the year-earlier period.
Total revenue increased 45.6% on an annual basis to 30.0 million kronor from 20.6 million kronor, and total operating expenses climbed 35.6% from the prior-year period to 27.4 million kronor from 20.2 million kronor.
Reported net income increased 75.0% on an annual basis to 2.8 million kronor, or 1 öre per share, from 1.6 million kronor, or 1 öre per share.
As of Oct. 27, US$1 was equivalent to 9.05 Swedish kronor.